FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC By Ogkologos - March 18, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma Induction ICI Combination Followed by CRT Is An Effective Bladder-Sparing Treatment in Patients with MIBC and Response Can Be Monitored by ctDNA MOST POPULAR The Childhood Cancer Data Initiative: Transforming the Pediatric Cancer Landscape through... August 15, 2019 From smart knives to virtual reality tumours: five innovations in understanding... August 29, 2022 How radiotherapy became a lifesaver – from X-rays to the proton... July 8, 2022 What’s happened to cancer clinical trials during the COVID-19 pandemic? November 4, 2020 Load more HOT NEWS Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than... Supplemental Breast Cancer Imaging Techniques Could Lead to Earlier Detection of... How to Talk With Your Children About Your Metastatic Cancer Prognosis Grabbing the Perfect Gift
